Leukaemia Trial, Recruiting NCT04794296 Sponsor: French Africa Pediatric Oncology Group Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT04794296
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children from birth up to 18 years old
  • Children who have been diagnosed with Acute Lymphoblastic Leukaemia (ALL) for the first time
  • Children whose leukaemia has not been treated with chemotherapy before
  • Children whose leukaemia cell type is classified as FAB L1 or L2 (specific subtypes identified under a microscope — confirm with trial site)

Who may not be able to join:

  • Children whose leukaemia is classified as ALL L3, also known as Burkitt type
  • Children who have previously received chemotherapy for their leukaemia
  • Children who have Trisomy 21 (also known as Down syndrome)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00(221)77 656 49 13.

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
French Africa Pediatric Oncology Group
Registry
ClinicalTrials.gov
Start date
15 November 2021
Est. completion
31 December 2028

Where this trial is recruiting

Côte d’Ivoire Guinea Senegal

Primary endpoints

Feasibility of these recommendations; Correct application of therapeutic recommendations; Complete Remission Rate (CR) close to 85% after induction; Ability to follow treatment:; Outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov